Health1 min read

Researchers explore possibility of a CTE blood test

By · Via STAT Health · Published by Everything Blog

In short

Merck, Eli Lilly, Pfizer, and Bristol Myers Squibb agreed to stop initiating new trials at Chinese military hospitals and within the Xinjiang region following congressional inquiries. AbbVie also committed to avoiding facilities tied to the People’s Liberation Army, but it declined to halt trials in Xinjiang to continue treating critical oncology patients. Meanwhile, U.S. health developments face regulatory friction as telehealth companies expand unapproved peptide offerings and a major scientific integrity report faces citation delays.

Key points

  • Heightened congressional oversight is driving American pharmaceutical giants to sever sen…: Heightened congressional oversight is driving American pharmaceutical giants to sever sensitive clinical research ties within China.
  • Telehealth platforms are marketing unapproved compounded peptides to consumers following…: Telehealth platforms are marketing unapproved compounded peptides to consumers following controversial guidance from agency leadership.
  • A prominent national report on scientific misconduct was paradoxically sidelined by basic…: A prominent national report on scientific misconduct was paradoxically sidelined by basic reference and citation errors.

Sources checked by our analysis pipeline: 1

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning, everyone. Are you a fan of “Grand Theft Auto”? Will your boss not give you the day off to play the video game you’ve been waiting 13 years for? Don’t worry, DJ Khaled and Dr. Xbox have you covered. Just click here and fill out the form. You’ll have a diagnosis and doctor’s note for Vitamin G deficiency faster than a telehealth company can prescribe you a peptide.

Which, speaking of …

Peptides go mainstream

Unapproved and off-label peptide drugs have long been popular with bodybuilders looking for an edge, but they could soon become a mass market health product, thanks to new initiatives from two popular telehealth companies.

Hims & Hers unveiled Thursday its Peptides+ program, offering two peptides alongside several compounded medications popular among peptide users. Noom announced its own offerings this week as well. This follows a decision by FDA leaders to — despite the concerns of staff scientists – allow compounders to produce six peptides…

Health